Drug Trial Radar · NCT06206408
A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Japanese Women Going Through Menopause
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
410
Actual
Start
Feb 16, 2024
Primary completion
Oct 22, 2025
Study completion Dec 18, 2025
Sponsor
- Lead sponsor
- Astellas Pharma IncAstellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Jan 16, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 40 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Hot flashes are the most common reason women going through menopause seek medical attention. Hormone replacement therapy, or HRT, is most often prescribed to treat hot flashes. However, HRT can't be used by all women or for as long as may be needed. Researchers want to find other ways to treat hot flashes. Fezolinetant is a medicine to treat hot flashes in women going through menopause. Fezolinetant is an approved medicine in the US. Further studies are needed before it is available in other regions such as Asia. This study will confirm if fezolintant helps reduce the number of hot flashes in Japanese women going through menopause. Women that want to take part in the study will be given an electronic handheld device with an app to track their hot flashes. Some women may be able to use the app on their own smartphone. Before the women are assigned a treatment, they will record information about their hot flashes. Women will either take a lower or higher dose of fezolinetant, or a placebo. This is decided by chance alone. The placebo looks like fezolinetant but will not have any medicine in it. The women will take 2 tablets of the study medicine (lower or higher dose of fezolinetant, or the placebo) once a day for up to 12 weeks. They will either take 1 tablet of fezolinetant (higher or lower dose) and 1 placebo tablet, or they will take 2 placebo tablets. The women will continue to record information about their hot flashes on the electronic device or their smartphone. During the study, the women will visit the study clinic a few times. At each visit they will be asked if they had any medical problems and will use an electronic device at the clinic to answer questions about how the hot flashes affect their daily life. Other checks will include a medical examination, vital signs (temperature, blood pressure and pulse). Some blood and urine samples will be taken for laboratory tests. At some visits, the women will also have an ECG to check their heart rhythm. Women who have a womb (uterus) will also have a test called a transvaginal ultrasound. A probe is gently placed inside the vagina. Sound waves will create a picture of the organs in the pelvis. This will allow the study doctor to look more closely at the uterus and surrounding organs. The last clinic visit will be 3 weeks after the women take their final tablets of the study medicine (1 tablet of lower or higher dose of fezolinetant and 1 placebo tablet, or 2 placebo tablets).
Conditions
- Hot Flashes
Interventions
FezolinetantDrug
oral
PlaceboDrug
oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean change from baseline in the frequency of mild to severe vasomotor symptoms (VMS)Time frame: Baseline and Week 8
Locations
64 sites in 1 country. Site status is shown where the registry gives one.
NISHIKAWA Women's Health Clinic
Sapporo, Japan
Chita Kosei Hospital
Chita-gun, Aichi-ken, Japan
Konan Kosei Hospital
Kōnan, Aichi-ken, Japan
Daido Clinic
Nagoya, Aichi-ken, Japan
MEITETSU Hospital
Nagoya, Aichi-ken, Japan
Toyota Kosei Hospital
Toyota-shi, Aichi-ken, Japan
Chiba Aoba Municipal Hospital
Chiba, Chiba, Japan
Aiiku Ladies Clinic
Funabashi-shi, Chiba, Japan
Tsujinaka Hospital Kashiwanoha
Kashiwa-shi, Chiba, Japan
Juno Vesta Clinic hatta
Matsudo-shi, Chiba, Japan
Fukuoka Mirai Hospital
Fukuoka, Fukuoka, Japan
Mori Ladies Clinic
Fukuoka, Fukuoka, Japan
Nishiguchi Clinic Fujinka
Fukushima, Fukushima, Japan
National Hospital Organization Takasaki General Medical Center
Takasaki-shi, Gunma, Japan
Sato Hospital
Takasaki-shi, Gunma, Japan
Sadamori Ladies Clinic
Hiroshima, Hiroshima, Japan
Kotoni Ladies Clinic
Sapporo, Hokkaido, Japan
M's Ladies Clinic
Sapporo, Hokkaido, Japan
Miyanomori Ladies' Clinic
Sapporo, Hokkaido, Japan
Social Medical Corporation Caress Sapporo Caress Memorial Hospital
Sapporo, Hokkaido, Japan
Kosumo Clinic
Kako-gun, Hyōgo, Japan
Mari Women'S Clinic
Nisinomiya-shi, Hyōgo, Japan
JA Toride Medical Center
Toride, Ibaraki, Japan
Tsukuba Urocare Clinic
Tsukuba, Ibaraki, Japan
National Hospital Organization Kanazawa Medical Center
Kanazawa, Ishikawa-ken, Japan
Asahi Clinic
Takamatsu, Kagawa-ken, Japan
Shonan Kamakura General Hospital
Kamakura, Kanagawa, Japan
Kawasakieki Fumi Ladies Clinic
Kawasaki-shi, Kanagawa, Japan
Koukan Clinic
Kawasaki-shi, Kanagawa, Japan
Shinkawasaki Kobiki Womens Clinic
Kawasaki-shi, Kanagawa, Japan
Motomachi Ladies Clinic
Yokohama, Kanagawa, Japan
Women's Clinic LUNA Yokohama Motomachi
Yokohama, Kanagawa, Japan
Rakuwakai Otowa Hospital
Kyoto, Kyoto, Japan
Chieko Yukika Lady's Clinic
Sendai, Miyagi, Japan
Social Medical Care Corporation Hosei-kai Marunouchi Hospital
Matsumoto-shi, Nagano, Japan
National Hospital Organization Beppu Medical Center
Beppu-shi, Oita Prefecture, Japan
Miyabi Uro-Gyne Clinic
Okayama, Okayama-ken, Japan
National Hospital Organization Osaka Minami Medical Center
Kawachinagano-shi, Osaka, Japan
Chayamachi Ladies Clinic
Osaka, Osaka, Japan
Chiharu Clinic
Osaka, Osaka, Japan
Showing 40 of 64 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.